Arca
Skip to content
Tools
Tools

ESR1, ESR2: Estrogen receptor

Family in Homo sapiens that 23 drugs act on.

  • Drugs that act on it: 23
  • Approved: 13
  • In phases 1 to 3: 10
  • Sponsors: 14

Who is on it, and how far along

Every drug ChEMBL records acting on ESR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 18
  • Other 5

Approved13

  • Estrogens, conjugated
  • Estriol
  • Toremifene
  • Bazedoxifene
  • Lasofoxifene
  • Estrogens, conjugated synthetic a
  • Cyclofenil
  • Diethylstilbestrol diphosphate
  • Estetrol anhydrous
  • Estrogens, esterified
  • Ospemifene
  • Quinestrol
  • Synthetic conjugated estrogens, b

Phase 34

  • Acolbifene
  • Afimoxifene
  • Arzoxifene
  • Droloxifene

Phase 25

  • Allylestrenol
  • Fispemifene
  • Idoxifene
  • LY2245461
  • MK-6913

Phase 11

  • CHF4227

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 14 of 23 act as: Estrogen receptor modulator; the rest name their own mechanism.
Estrogens, conjugatedBoxed warningApprovedPfizerOtherAgonistEstrogen receptor agonist16
EstriolApprovedMeLSyTech, LtdSmall moleculeModulator10
ToremifeneBoxed warningApprovedKyowa KirinSmall moleculeModulator8
BazedoxifeneApprovedWyeth is now a wholly owned subsidiary of PfizerSmall moleculeModulator6
LasofoxifeneApprovedAzure BiotechSmall moleculeModulator3
Estrogens, conjugated synthetic aBoxed warningApprovedAspenOtherAgonistEstrogen receptor agonist1
CyclofenilWithdrawnApproved—Small moleculeModulator0
Diethylstilbestrol diphosphateApprovedBayerSmall moleculeAgonistEstrogen receptor agonist0
Estetrol anhydrousApprovedEstetraSmall moleculeAgonistEstrogen receptor agonist0
Estrogens, esterifiedBoxed warningApprovedSolvayOtherAgonistEstrogen receptor agonist0
OspemifeneBoxed warningApprovedDuchesnaySmall moleculeModulator0
QuinestrolApprovedPfizerSmall moleculeAgonistEstrogen receptor agonist0
Synthetic conjugated estrogens, bBoxed warningApprovedTeva Pharmaceutical IndustriesOtherAgonistEstrogen receptor agonist0
AcolbifenePhase 3—Small moleculeModulator1
AfimoxifenePhase 3Ascend Therapeutics USSmall moleculeModulator1
ArzoxifenePhase 3Eli LillySmall moleculeModulator0
DroloxifenePhase 3—Small moleculeModulator0
AllylestrenolPhase 2—Small moleculeAgonistEstrogen receptor agonist0
FispemifenePhase 2QuatRx Pharmaceuticals CompanySmall moleculeModulator0
IdoxifenePhase 2—Small moleculeModulator0
LY2245461Phase 2—OtherModulator0
MK-6913Phase 2—Small moleculeAgonistEstrogen receptor agonist0
CHF4227Phase 1—Small moleculeModulator0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 35 in all, from ClinicalTrials.gov.
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerEstrogens, conjugatedPhase 3Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOct 23, 2026
Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast CancerToremifeneNot applicableNot yet recruitingHenan Cancer HospitalJul 16, 2026
Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast CancerEstrogens, conjugated, Estrogens, conjugated synthetic aPhase 2Not yet recruitingTang-Du HospitalJun 1, 2026
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyToremifenePhase 2RecruitingFujian Cancer HospitalMay 12, 2026
A Study of Single Dose of BL0175 in Postmenopausal WomenEstrogens, conjugatedPhase 1Not yet recruitingShanghai Best-Link Bioscience, LLCJan 26, 2026
The Effects of Adjunctive Therapy With Vaginal Tablets Lactobacillus Acidophilus and a Low Dose Estriol (Gynoflor®) to Prolong Pregnancy Time in Preterm Labor, A Randomized Controlled TrialEstriolNot applicableNot yet recruitingQueen Savang Vadhana Memorial Hospital, ThailandJan 15, 2026
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast CancerEstrogens, conjugatedPhase 1 / Phase 2RecruitingKristina A. FanucciSep 30, 2025
Microbiome-Modulating Prophylaxis RCT: Antibiotic vs Gynoflor in Postmenopausal Women With Recurrent CystitisEstriolPhase 4RecruitingMahidol UniversitySep 22, 2025
De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority TrialToremifenePhase 3Not yet recruitingFudan UniversitySep 4, 2025
A Clinical Study of SYS6023 in Patients With Advanced Solid TumorsEstrogens, conjugatedPhase 1RecruitingCSPC Megalith Biopharmaceutical Co.,Ltd.Aug 8, 2025
Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse SurgeryEstrogens, conjugatedPhase 3RecruitingSarah WozneyJun 22, 2025
Er:YAG Laser Combined With Vaginal Estriol for Genitourinary Syndrome of MenopauseEstriolNot applicableRecruitingUniversity of Nove de JulhoMar 13, 2025
Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner SyndromeEstriolPhase 4RecruitingAarhus University HospitalAug 26, 2024
Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner SyndromeEstriolPhase 4RecruitingAarhus University HospitalAug 9, 2024
Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast CancerToremifenePhase 2RecruitingTianjin Medical University Cancer Institute and HospitalJul 10, 2024
Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive BladderEstrogens, conjugatedPhase 4RecruitingMackay Memorial HospitalJun 28, 2024
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerEstrogens, conjugatedPhase 2RecruitingDana-Farber Cancer InstituteJun 3, 2024
Effect of Local Estriol Treatment Before Vaginal Repair SurgeryEstriolPhase 3Active, not recruitingHatice Tukenmez KurnazApr 30, 2024
Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal WomenLasofoxifenePhase 2RecruitingAzure Biotech Inc.Jan 9, 2024
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast CancerAcolbifenePhase 2RecruitingNational Cancer Institute (NCI)Jul 12, 2023
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)ToremifenePhase 3RecruitingFudan UniversityJun 6, 2023
Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast CancerToremifenePhase 2RecruitingFudan UniversityMay 16, 2023
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationLasofoxifenePhase 3RecruitingLeonaBioJan 25, 2023
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After LumpectomyToremifenePhase 2RecruitingUNC Lineberger Comprehensive Cancer CenterJul 25, 2022
Treatment of Vaginal Atrophy With Low Intensity Nanosecond Neodymium LaserEstriolNot applicableRecruitingMeLSyTech, LtdApr 19, 2022
Endometriosis and Microvascular Dysfunction; Simvastatin and DuaveeBazedoxifenePhase 4Enrolling by invitationPenn State UniversitySep 28, 2021
Reducing Pregnancy Risks: The Mastery Lifestyle InterventionEstriolNot applicableRecruitingMicrogen LLCAug 19, 2021
Phase IIB Trial of Bazedoxifene Plus Conjugated EstrogensBazedoxifenePhase 2Active, not recruitingUniversity of Kansas Medical CenterMar 29, 2021
Affect of Duavive on Mood & Anxiety SymptomsBazedoxifenePhase 1RecruitingSt. Joseph's Healthcare HamiltonJul 20, 2020
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)ToremifenePhase 2Active, not recruitingFudan UniversityMay 12, 2020
Bazedoxifene -Treatment for Women With SchizophreniaBazedoxifenePhase 4RecruitingThe AlfredOct 3, 2019
Advancing Postmenopausal Preventive TherapyBazedoxifenePhase 2Active, not recruitingUniversity of Southern CaliforniaSep 25, 2019
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One BreastAfimoxifenePhase 2Active, not recruitingNorthwestern UniversityJul 5, 2019
Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis PatientsBazedoxifenePhase 2RecruitingShinshu UniversityNov 27, 2018
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerLasofoxifenePhase 2RecruitingQuantumLeap Healthcare CollaborativeJan 5, 2010

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2093866, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.